Inference of hierarchical regulatory network of estrogen-dependent breast cancer through ChIP-based data

BackgroundGlobal profiling of in vivo protein-DNA interactions using ChIP-based technologies has evolved rapidly in recent years. Although many genome-wide studies have identified thousands of ERα binding sites and have revealed the associated transcription factor (TF) partners, such as AP1, FOXA1 and CEBP, little is known about ERα associated hierarchical transcriptional regulatory networks.ResultsIn this study, we applied computational approaches to analyze three public available ChIP-based datasets: ChIP-seq, ChIP-PET and ChIP-chip, and to investigate the hierarchical regulatory network for ERα and ERα partner TFs regulation in estrogen-dependent breast cancer MCF7 cells. 16 common TFs and two common new TF partners (RORA and PITX2) were found among ChIP-seq, ChIP-chip and ChIP-PET datasets. The regulatory networks were constructed by scanning the ChIP-peak region with TF specific position weight matrix (PWM). A permutation test was performed to test the reliability of each connection of the network. We then used DREM software to perform gene ontology function analysis on the common genes. We found that FOS, PITX2, RORA and FOXA1 were involved in the up-regulated genes.We also conducted the ERα and Pol-II ChIP-seq experiments in tamoxifen resistance MCF7 cells (denoted as MCF7-T in this study) and compared the difference between MCF7 and MCF7-T cells. The result showed very little overlap between these two cells in terms of targeted genes (21.2% of common genes) and targeted TFs (25% of common TFs). The significant dissimilarity may indicate totally different transcriptional regulatory mechanisms between these two cancer cells.ConclusionsOur study uncovers new estrogen-mediated regulatory networks by mining three ChIP-based data in MCF7 cells and ChIP-seq data in MCF7-T cells. We compared the different ChIP-based technologies as well as different breast cancer cells. Our computational analytical approach may guide biologists to further study the underlying mechanisms in breast cancer cells or other human diseases.

[1]  R. Fisher.  019: On the Interpretation of x2 from Contingency Tables, and the Calculation of P. , 1922 .

[2]  Victor X Jin,et al.  Loss of Estrogen Receptor Signaling Triggers Epigenetic Silencing of Downstream Targets in Breast Cancer , 2004, Cancer Research.

[3]  Suresh Cuddapah,et al.  The genomic landscape of histone modifications in human T cells , 2006, Proceedings of the National Academy of Sciences.

[4]  H. Stunnenberg,et al.  ChIP‐Seq of ERα and RNA polymerase II defines genes differentially responding to ligands , 2009, The EMBO journal.

[5]  Rachel Schiff,et al.  Estrogen-receptor biology: continuing progress and therapeutic implications. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  R. Schiff,et al.  Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. , 2008, Cancer research.

[7]  E. Liu,et al.  An Oestrogen Receptor α-bound Human Chromatin Interactome , 2009, Nature.

[8]  Tim Hui-Ming Huang,et al.  Isolating human transcription factor targets by coupling chromatin immunoprecipitation and CpG island microarray analysis. , 2002, Genes & development.

[9]  P. Chambon,et al.  Activation of the ovalbumin gene by the estrogen receptor involves the Fos-Jun complex , 1990, Cell.

[10]  T. Speed,et al.  Multiple transcription factor elements collaborate with estrogen receptor alpha to activate an inducible estrogen response element in the NKG2E gene. , 2007, Endocrinology.

[11]  Sumio Sugano,et al.  The functional consequences of alternative promoter use in mammalian genomes. , 2008, Trends in genetics : TIG.

[12]  V. Giguère,et al.  Functional genomics identifies a mechanism for estrogen activation of the retinoic acid receptor alpha1 gene in breast cancer cells. , 2005, Molecular endocrinology.

[13]  S. Squazzo,et al.  Using ChIP-chip technology to reveal common principles of transcriptional repression in normal and cancer cells. , 2008, Genome research.

[14]  Clifford A. Meyer,et al.  Genome-wide analysis of estrogen receptor binding sites , 2006, Nature Genetics.

[15]  A. Sandelin,et al.  Applied bioinformatics for the identification of regulatory elements , 2004, Nature Reviews Genetics.

[16]  Céline Lefebvre,et al.  From the Cover: Location analysis of estrogen receptor alpha target promoters reveals that FOXA1 defines a domain of the estrogen response. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[17]  F. Stossi,et al.  Whole-Genome Cartography of Estrogen Receptor α Binding Sites , 2007, PLoS genetics.

[18]  A. Llombart‐Bosch,et al.  CtIP Silencing as a Novel Mechanism of Tamoxifen Resistance in Breast Cancer , 2007, Molecular Cancer Research.

[19]  M. Abdelrahim,et al.  Small Inhibitory RNA Duplexes for Sp1 mRNA Block Basal and Estrogen-induced Gene Expression and Cell Cycle Progression in MCF-7 Breast Cancer Cells* , 2002, The Journal of Biological Chemistry.

[20]  V. Ferrans,et al.  Competition for p300 Regulates Transcription by Estrogen Receptors and Nuclear Factor-&kgr;B in Human Coronary Smooth Muscle Cells , 2000, Circulation research.

[21]  Allen D. Delaney,et al.  Genome-wide profiles of STAT1 DNA association using chromatin immunoprecipitation and massively parallel sequencing , 2007, Nature Methods.

[22]  Xin Chen,et al.  TRANSFAC: an integrated system for gene expression regulation , 2000, Nucleic Acids Res..

[23]  Victor X. Jin,et al.  Genomic Targets of the KRAB and SCAN Domain-containing Zinc Finger Protein 263* , 2009, The Journal of Biological Chemistry.

[24]  Sandya Liyanarachchi,et al.  Combinatorial analysis of transcription factor partners reveals recruitment of c-MYC to estrogen receptor-alpha responsive promoters. , 2006, Molecular cell.

[25]  C. Daub,et al.  BMC Systems Biology , 2007 .

[26]  Myles A Brown,et al.  Estrogen receptor target gene: an evolving concept. , 2006, Molecular endocrinology.

[27]  X. Chen,et al.  The Oct4 and Nanog transcription network regulates pluripotency in mouse embryonic stem cells , 2006, Nature Genetics.

[28]  Lang Li,et al.  Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. , 2006, Cancer research.

[29]  Christoph Plass,et al.  ChIP-chip comes of age for genome-wide functional analysis. , 2006, Cancer research.

[30]  Leah Barrera,et al.  A high-resolution map of active promoters in the human genome , 2005, Nature.

[31]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[32]  Sarah L Vowler,et al.  Cooperative interaction between retinoic acid receptor-alpha and estrogen receptor in breast cancer. , 2010, Genes & development.

[33]  Henriette O'Geen,et al.  Identification of an OCT4 and SRY regulatory module using integrated computational and experimental genomics approaches. , 2007, Genome research.

[34]  T. Mikkelsen,et al.  Genome-wide maps of chromatin state in pluripotent and lineage-committed cells , 2007, Nature.

[35]  Dustin E. Schones,et al.  High-Resolution Profiling of Histone Methylations in the Human Genome , 2007, Cell.

[36]  J. Winderickx,et al.  Inferring transcriptional modules from ChIP-chip, motif and microarray data , 2006, Genome Biology.

[37]  P. Shannon,et al.  Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.

[38]  Andrew G. Clark,et al.  Genomic Analyses of Transcription Factor Binding, Histone Acetylation, and Gene Expression Reveal Mechanistically Distinct Classes of Estrogen-Regulated Promoters , 2007, Molecular and Cellular Biology.

[39]  R. Fisher.  On the Interpretation of χ2 from Contingency Tables, and the Calculation of P , 2010 .

[40]  J. Jameson,et al.  Estrogen Receptor Binding to DNA Is Not Required for Its Activity through the Nonclassical AP1 Pathway* , 2001, The Journal of Biological Chemistry.

[41]  John J. Wyrick,et al.  Genome-wide location and function of DNA binding proteins. , 2000, Science.

[42]  Sandya Liyanarachchi,et al.  Identifying estrogen receptor α target genes using integrated computational genomics and chromatin immunoprecipitation microarray , 2004 .

[43]  Clifford A. Meyer,et al.  Chromosome-Wide Mapping of Estrogen Receptor Binding Reveals Long-Range Regulation Requiring the Forkhead Protein FoxA1 , 2005, Cell.

[44]  C. Klinge,et al.  Estrogen receptor interaction with co-activators and co-repressors☆ , 2000, Steroids.

[45]  A. Mortazavi,et al.  Genome-Wide Mapping of in Vivo Protein-DNA Interactions , 2007, Science.

[46]  Simak Ali,et al.  Regulation of ERBB2 by oestrogen receptor–PAX2 determines response to tamoxifen , 2008, Nature.

[47]  I. Simon,et al.  Reconstructing dynamic regulatory maps , 2007, Molecular systems biology.

[48]  Victor X. Jin,et al.  W-ChIPMotifs: a web application tool for de novo motif discovery from ChIP-based high-throughput data , 2009, Bioinform..